Provider review
Science & Co review: its worked example lands exactly on the trial average, and never says so
Science & Co shows you a progress card: 222 pounds down to 189, labeled "15% lost on average". Do the division and it comes to 14.9%. STEP 1, the trial nearly every semaglutide claim rests on, reported a mean reduction of about 15% over 68 weeks. So the number is right — arguably the most carefully chosen figure in this batch. What's missing is where it came from. It sits under a heading reading "last check in", beside a line about logging your progress, with no trial, journal or year anywhere near it.
Its worked example lands on STEP 1's mean almost exactly, and it is dressed as a patient's check-in rather than cited as a trial.
Worth trusting if
- You want a seller that states its corporate form and its regulatory position rather than leaving both blank
- You want a figure that survives being checked, which this one does
- You want side effects described plainly rather than hidden behind a click
Be skeptical if
- You want the source named beside the number, because no trial is cited anywhere on the site
- You want to know which pharmacy makes your medication
- You want the tirzepatide page to say what tirzepatide does, because it does not
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens science.co. A link is not a recommendation to take anything.
Provenance
What Science & Co actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $79 a month on the twelve-month plan, against a $149 reference rate.
- Compounded tirzepatide injection — $125 a month on the twelve-month plan, against a $199 reference rate.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Science & Co.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Science & Co’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“222 lbs → 189 lbs. 15% lost on average. Steady, provider guided progress you can track month to month. Same Price, Any Dose.”
Read on the Science & Co site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults with a body-mass index of 30 or above, or 27 or above with a weight-related condition. Reported a mean weight reduction of about 15% on semaglutide 2.4 mg against about 2% on placebo.
Doing the sum is what settles this. A drop from 222 to 189 pounds is 33 pounds, which is 14.9% of the starting weight — and STEP 1's mean reduction was about 15%. Whoever built that card worked from the trial rather than from marketing instinct, and the figure is quoted as an average rather than as a promise. Two things keep it from being a model citation. The card is framed as a patient's check-in rather than as a trial result, so a reader has no way to know they are looking at published data. And no timeline is attached, which cuts both ways: nothing has been compressed, but nothing tells you the trial took 68 weeks to get there.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Compounded Tirzepatide (Injection), prescribed by a licensed provider and built around your history, your goals and how your body actually responds. Same Price, Any Dose.”
Read on the Science & Co site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. Reported a mean reduction of roughly 20% at the top dose.
The tirzepatide page makes no outcome claim at all — no percentage, no worked example, no timeline. It describes what the drug is and how the plan works, and leaves the result unstated. That is a defensible position rather than an evasive one, though it does mean the page selling the more effective of the two molecules says less about what it does than the page selling the other. The flat-price promise is repeated here and is a commercial claim rather than a clinical one.2
Dispensing chain
Who actually fills your prescription
Read the full account
Science & Co names no pharmacy — but it does something rarer than naming one, which is to say what it is not. Its terms state twice that the company is not a 503A or 503B compounding facility, meaning it neither makes drugs to order nor manufactures them in bulk itself, and adds that it may offer compounded medications from registered U.S. facilities. Across both Worth registries the usual finding is that neither of those regulatory terms appears anywhere on a seller's site at all. That is a clearer position than most of this market takes, and it still leaves the actual facility unnamed, along with every clinician.
Read on the Science & Co site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere on the site. What Science & Co does publish, and unusually, is a set of short plain-language guides written by its clinical team — protein on a GLP-1, side effects and when to call, storing and handling the medication — each marked with a reading time. Its side-effect line is refreshingly unglamorous: usually nausea, and usually early. None of that is a test result, and none of it is dressed up as one.
Read on the Science & Co site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Science & Co publishes no list of states and claims no nationwide coverage, on its product pages, its FAQ or its terms, checked on September 13, 2026. Its terms govern use of the website rather than describing a service area.
Read the full licensing claim
The operator is named and its corporate form and state are given: Science and Co, Inc., a Delaware corporation. A telephone number is published. No street address appears, and no clinician, medical director or advisory panel is named.
Read on the Science & Co site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its worked example is arithmetically sound — 222 to 189 pounds is 14.9%, and the trial mean was about 15%.
- The figure is called an average rather than sold as a promise.
- It says outright that it is not a compounding facility itself, a distinction most sellers never raise.
Show 5 more
- It names its corporate form and its state of incorporation in its own terms.
- Its FAQ volunteers that the advertised price is the twelve-month plan, rather than leaving you to find out.
- Side effects are described plainly — usually nausea, usually early — without an accordion to open.
- It publishes short clinical guides on protein, storage and when to call, each with a reading time.
- No FDA warning letter under the registered company name.
- No trial is named anywhere on the site, so its best number arrives with no way to check it.
- That number sits under a "last check in" heading, which reads as a patient's result rather than published data.
- No timeline is given, so nothing tells you the trial took 68 weeks to reach that average.
Show 5 more
- The tirzepatide page makes no outcome claim at all, on the more effective of the two molecules.
- No pharmacy is named — saying it is not one itself is not the same as saying which one it uses.
- No clinician is named, though guides are attributed to a clinical team.
- Ozempic, Wegovy and Zepbound are listed without prices or claims, so what is buyable is unclear.
- No street address is published.
Verdict
The bottom line
This is the rare case where a seller's number survives being checked and still leaves you worse informed than it should. The 15% is real, it comes from the right trial, and Science & Co never tells you that. Ask them to put STEP 1 next to the figure — and separately, ask which pharmacy fills the prescription, because saying they are not one themselves does not answer it.
Opens science.co. A link is not a recommendation to take anything.
Do the division
Science & Co shows a progress card:
222 lbs → 189 lbs
15% lost on average
33 pounds off 222 is 14.86%.
STEP 1 randomized 1,961 adults for 68 weeks and reported a mean weight reduction of about 15% on semaglutide 2.4 mg. 1
The example lands on the trial mean to within a rounding. Whoever built that card worked from the published result rather than picking a number that would sell — and they labeled it an average, not a promise.
We had this graded as unsupported before running the arithmetic. The arithmetic is what changed it.
Full analysis — 3 more sectionsSo what's wrong with it · The sentence almost nobody else writes · The quieter page
So what's wrong with it
Where it sits. The card appears under a heading reading "LAST CHECK IN", beside:
"Progress you can see. Log what changes and your provider adjusts with you."
That's the frame of a patient's dashboard. A reader meets a trial average dressed as somebody's month. No trial, no journal, no year appears anywhere near it — or anywhere on the site.
There's also no timeline. Nothing cuts a 68-week result down to six months, which is the usual failure. But nothing tells you it took 68 weeks either.
The sentence almost nobody else writes
From its terms, stated twice:
"Science and Co, Inc. is not a 503A or 503B compounding facility."
Those are the two categories of pharmacy that make drugs to order or in bulk. Across both of our registries, the normal finding is that neither term appears on a seller's site at all.
Science & Co raises the distinction unprompted and puts itself on the right side of it. It still doesn't name the facility it actually uses — but it has told you something real about what it is, which is more than most manage.
The quieter page
The tirzepatide page makes no outcome claim whatsoever. No percentage, no example, no timeline.
That's defensible. It's also odd: the page selling the molecule with the larger published effect 2 says less about what it does than the page selling the other one.
Questions
Frequently asked questions
Is the 15% figure real?
Yes, and it checks out. The worked example on the page — 222 pounds down to 189 — is a 14.9% reduction, and STEP 1 reported a mean of about 15% over 68 weeks. It's the most carefully chosen number in this batch of sellers, and the site never tells you where it came from.
How long does that take?
In the trial, 68 weeks — roughly sixteen months. Science & Co gives no timeline at all, which at least means it hasn't compressed the result the way some sellers do. It also means nothing on the page sets your expectations about pace.
What does it mean that Science & Co isn't a compounding facility?
Those are the two categories of pharmacy allowed to make drugs to order or in bulk. Science & Co is saying it isn't one — it arranges care and the medication comes from a facility elsewhere. Most sellers never raise the distinction, so stating it is genuinely useful, even though the facility itself is still unnamed.
Why doesn't the tirzepatide page say what tirzepatide does?
The site doesn't explain that. Its tirzepatide page describes the plan and the price and makes no outcome claim, while its semaglutide page carries the worked example. In published trials tirzepatide produced the larger average reduction of the two.
Do those trials apply to compounded medication?
Only in part, and this is true of nearly every seller we review. STEP 1 tested the manufacturer's approved semaglutide, not a compounded preparation made to order by a pharmacy. Nothing published compares the two directly.
Glossary
Key terms
Show definitions
- 503A and 503B
- The two categories of compounding pharmacy under US law. A 503A makes a drug to order for one named patient; a 503B is an outsourcing facility that can make batches. Neither produces an FDA-approved finished product.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
Compare
Others selling what Science & Co sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Science & Co's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, mean weight reduction of about 15%. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.